Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04670328

Enrollment

101

Registered

2020-12-17

Start date

2020-05-01

Completion date

2020-07-31

Last updated

2020-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Covid-19 disease, Neutrophil to Lymphocyte ratio, hematological manifestations

Brief summary

The hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.

Detailed description

Objective: COVID-19 virus involves respiratory as well as other body systems including cardiovascular, gastrointestinal, neurological, immunological and hematopoietic system. Patient of covid-19 pneumonia presents with wide range of hemostatic abnormalities. These hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity. Material and Method: This was a retrospective study, conducted in Department of Pathology and Department of medicine, FMH college of Medicine and Dentistry from May 2020 to July 2020. Total of 101, confirmed cases of covid-19 disease, both genders between 17 to 75-year age were included. Hematological parameters were compared in mild, moderate, severe and critical disease group. Continuous variables were analyzed by using non parametric, Kruskal Wallis test while categorical variables were analyzed by chi-square test.

Interventions

DIAGNOSTIC_TESTnot required

Diagnostic tests( hematological parameters) were assessed.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

17 Years to 75 Years

Healthy volunteers

Inclusion criteria

* diagnosed cases of covid-19 disease * Both genders * 17 to 75 year age

Exclusion criteria

* known case of chronic liver disease * known hematological diseases were excluded

Design outcomes

Primary

Measure	Time frame	Description
complete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio	3 months	disease severity was assessed on basis of hematological parameters.

Secondary

Measure	Time frame	Description
PT, APTT and D-dimer	3 months	improvement in PT, APTT and D-dimer levels were assessed

Other

Measure	Time frame	Description
LDH, serum ferritin level	3 months	improvement in LDH and were assessed

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026